Myriad Genetics Prolaris test predicts risk of prostate cancer recurrence Myriad Genetics announced that a study published in the Journal of Clinical Oncology demonstrated that its Prolaris test, which analyzes the expression level of 46 cell cycle progression genes, accurately predicted the elevated risk for prostate cancer recurrence in 413 men who had undergone a radical prostatectomy. The study entitled "Validation of a panel of cell cycle progression genes for improved risk-stratification in a contemporary radical prostatectomy cohort," concluded that the Prolaris test effectively stratified men by risk of biochemical recurrence.
News For MYGN From The Last 14 Days
Check below for free stories on MYGN the last two weeks.
Myriad Genetics advises prior BRACAnalysis news release be disregarded Myriad Genetics advised that readers should disregard the news release, "Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis" issued April 7 by the company over GlobeNewswire.
Myriad Genetics price target raised to $42 from $34 at Piper Jaffray Piper Jaffray raised its price target for Myriad Genetics shares to $42 to reflect CMS' recent decision to increase BRCA reimbursement. The firm keeps an Overweight rating on the stock.
Myriad Genetics price target raised to $40 from $28 at Mizuho Mizuho raised Myriad's price target to $40 from $28 following the better than expected CMS pricing for BRCA testing. Shares are Neutral rated.